If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 7 of 7
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Objective
This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Objective
Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)
Protocol No
ECOG-EA8212-BRIDGE
Categories
A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE
Objective
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)
Protocol No
ANTHOS-ANT-007
Categories
Cancer,
Eye/Orbital Cancers,
Skin Cancers,
Cervix,
Lip, Oral Cavity and Pharynx,
Sarcoma,
Other Gastrointestinal,
Other Blood Related,
Pancreas/Liver,
Uterine,
Other Respiratory,
Gynecologic Cancers,
Brain and Spine Cancers,
Bladder,
Lung,
Head and Neck Cancers,
Leukemia,
Prostate,
Esophagus,
Thoracic Cancers,
Colorectal,
Hematologic/Blood Related Cancers,
Gastrointestinal Cancers,
Kidney,
Endocrine Cancers,
Prostate and Urologic Cancers,
Multiple Myeloma,
Breast Cancers
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Objective
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer,
Other Skin,
Thoracic Cancers,
Gynecologic Cancers,
Other Gastrointestinal,
Early Phase/Multiple Disease Site Cancers,
Lip, Oral Cavity and Pharynx,
Melanoma, Skin,
Esophagus,
Bladder,
Pancreas/Liver,
Prostate,
Skin Cancers,
Kidney,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Colorectal,
Gastrointestinal Cancers,
Sarcoma,
Breast Cancers
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
Objective
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Protocol No
NRG-BN013
Categories
Cancer,
Other Skin,
Bladder,
Colorectal,
Cervix,
Other Gynecologic,
Breast Cancers,
Esophagus,
Prostate,
Larynx,
Other Gastrointestinal,
Esophagus,
Gynecologic Cancers,
Other Respiratory,
Melanoma, Skin,
Prostate and Urologic Cancers,
Pancreas/Liver,
Eye/Orbital Cancers,
Thoracic Cancers,
Lip, Oral Cavity and Pharynx,
Head and Neck Cancers,
Gastrointestinal Cancers,
Endocrine Cancers,
Skin Cancers,
Brain and Spine Cancers
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Objective
Testing the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy after surgical removal of the bladder for bladder cancer treatment.
Protocol No
ALLIANCE-A032103-MODERN
Categories
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
Objective
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Protocol No
SWOG-S2012